3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
17
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Prostate Adenocarcinoma
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Temozolomide
29
Bevacizumab
15
Radiotherapy
13
antineoplaston AS 2-1
8
antineoplaston A10
8
Everolimus
7
Radiation
6
Erlotinib Hydrochloride
6
Radiotherapy, Intensity-Modulated
5
Lomustine
4
veliparib
3
palbociclib
3
Vorinostat
3
Sunitinib
3
Radiotherapy, Conformal
3
Magnetic Resonance Spectroscopy
3
Carmustine
3
Carboplatin
3
temsirolimus
2
selinexor
2
poly ICLC
2
etoposide phosphate
2
cabozantinib
2
Sirolimus
2
Nivolumab
2
Irinotecan
2
Immunoglobulin G
2
Imatinib Mesylate
2
Etoposide
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Astrocytoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts